PRESS RELEASE published on 01/15/2024 at 13:00, 8 months 4 days ago Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study Theralase Technologies Inc. provides an update on its Phase II Non-Muscle Invasive Bladder Cancer clinical study, demonstrating favorable interim clinical data that exceeds the International Bladder Cancer Group's guidelines. With 63 patients treated to date, the study shows promising results, potentially leading to Break Through Designation and Accelerated Approval. The Company plans to complete enrollment and delivery of the primary Study II Treatment for all patients in 2024, with potential Health Canada and FDA approval expected by 2026 / 2027. Theralase Technologies Inc. Bladder Cancer Clinical Study Break Through Designation Accelerated Approval Health Canada And FDA Approval
PRESS RELEASE published on 11/30/2023 at 00:30, 9 months 19 days ago Theralase Release’s 3Q2023 Interim Financial Statements Theralase Technologies Inc. has released the Company's 3Q2023 unaudited condensed interim consolidated Financial Statements, showing a 13% decrease in total revenue and other significant financial highlights Financial Statements Theralase Technologies Inc. Clinical Research 3Q2023 Revenue Decrease
PRESS RELEASE published on 11/29/2023 at 22:35, 9 months 20 days ago Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
PRESS RELEASE published on 11/17/2023 at 22:30, 10 months 2 days ago Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
PRESS RELEASE published on 10/23/2023 at 23:55, 10 months 27 days ago Theralase(R) Announces Brokered LIFE Financing
PRESS RELEASE published on 10/23/2023 at 13:00, 10 months 27 days ago Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
PRESS RELEASE published on 10/16/2023 at 13:00, 11 months 3 days ago Theralase(R) Provides Update on Bladder Cancer Clinical Study
PRESS RELEASE published on 10/05/2023 at 13:00, 11 months 14 days ago Theralase(R) Files US Patent for Enhanced Immunotherapy
PRESS RELEASE published on 09/29/2023 at 13:00, 11 months 20 days ago Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
PRESS RELEASE published on 09/27/2023 at 13:00, 11 months 22 days ago Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer
Published on 09/19/2024 at 23:15, 53 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 1 hour 8 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/19/2024 at 20:15, 3 hours 53 minutes ago Living Security Named a Leader in Human Risk Management, Closely Watched Tech Industry Report
Published on 09/19/2024 at 21:09, 2 hours 58 minutes ago EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Published on 09/19/2024 at 18:44, 5 hours 23 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/19/2024 at 18:03, 6 hours 5 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/19/2024 at 17:52, 6 hours 15 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 6 hours 15 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:45, 6 hours 23 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 6 hours 23 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 6 hours 23 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)